Inscripta is developing the world’s first benchtop platform for scalable digital genome engineering to empower scientists whose gene editing research is stifled by current technical and licensing limitations. The company’s advanced CRISPR-based platform offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. By providing this unique platform and engaging in collaborative business practices, the company enables scientists to realize a new era of biological discovery.

CEO

Kevin Ness, CEO

OAK HC/FT PARTNER

Annie Lamont

Sector

Investment Stage

Status

Healthcare

Growth

Private